Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
55 GBX | +5.77% | +4.76% | -11.29% |
Sales 2024 * | 15.35M 19.17M | Sales 2025 * | 103M 129M | Capitalization | 992M 1.24B |
---|---|---|---|---|---|
Net income 2024 * | -83M -104M | Net income 2025 * | -38M -47.47M | EV / Sales 2024 * | 52.7 x |
Net cash position 2024 * | 184M 230M | Net cash position 2025 * | 146M 183M | EV / Sales 2025 * | 8.19 x |
P/E ratio 2024 * |
-23.9
x | P/E ratio 2025 * |
-80.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
Latest transcript on Verona Pharma plc
1 day | +5.77% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 20-01-31 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 20-02-29 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16-06-16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 16-09-11 |
David Ebsworth
CHM | Chairman | 69 | 14-11-30 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- VRNA Stock
- VRP Stock